Credit Suisse Group Reiterates “Outperform” Rating for Haleon (LON:HLN)

Haleon (LON:HLNGet Rating)‘s stock had its “outperform” rating reissued by Credit Suisse Group in a report issued on Wednesday, LSE.Co.UK reports. They currently have a GBX 376 ($4.66) price objective on the stock. Credit Suisse Group’s price objective indicates a potential upside of 19.67% from the stock’s previous close.

Several other equities analysts also recently issued reports on the stock. Barclays downgraded shares of Haleon to an “overweight” rating and upped their price objective for the company from GBX 289 ($3.58) to GBX 360 ($4.46) in a research note on Wednesday, December 7th. Cheuvreux began coverage on Haleon in a research report on Friday, October 28th. They issued a “hold” rating and a GBX 275 ($3.40) target price for the company. Kepler Capital Markets began coverage on Haleon in a research note on Friday, October 28th. They set a “hold” rating and a $275.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 300 ($3.71) price objective on shares of Haleon in a research note on Thursday, December 8th. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company. According to data from, the company currently has a consensus rating of “Hold” and an average target price of GBX 314.50 ($3.89).

Haleon Stock Performance

Shares of LON:HLN traded up GBX 0.95 ($0.01) during trading on Wednesday, hitting GBX 314.20 ($3.89). The company’s stock had a trading volume of 6,871,371 shares, compared to its average volume of 12,005,349. Haleon has a fifty-two week low of GBX 241.17 ($2.99) and a fifty-two week high of GBX 337.40 ($4.18). The firm’s 50 day simple moving average is GBX 310.02. The company has a debt-to-equity ratio of 38.18, a current ratio of 3.43 and a quick ratio of 0.93. The stock has a market cap of £29.02 billion and a P/E ratio of 1,963.75.

About Haleon

(Get Rating)

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.

Read More

Analyst Recommendations for Haleon (LON:HLN)

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with's FREE daily email newsletter.